ABCD-2V

ABCD-2V

Appropriate Blood Pressure Control in Diabetes—Part 2 with Valsartan. A clinical trial comparing the effects of intensive vs. moderate blood pressure control with valsartan on nephropathy and vascular complications in normotensive and hypertensive type 2 diabetics.
References in periodicals archive ?
Diovan is also the primary agent in the ABCD-2V clinical trial, designed to compare the effects of moderate versus intensive blood pressure control on the prevention and progression of diabetes complications in both normotensive and hypertensive adult (type II) diabetes patients.
Besides Val-HeFT, three other major international trials are investigating the Diovan promise of prolonging and improving patients' lives across a variety of cardiovascular disease states, including: VALIANT (post-myocardial infarction patients); VALUE (high-risk patients with hypertension); and ABCD-2V (involving adult type-2 diabetes patients with either normal or high blood pressure).
The trials, which include Val-HeFT, VALUE, VALIANT and ABCD-2V, examine the effect of Diovan beyond its existing indication for hypertension.
The trials, which include Val-HeFT, VALUE, VALIANT, and ABCD-2V, will examine the effects of Diovan beyond its existing indication for hypertension.
The ABCD-2V trial will continue for the next five years to examine the effects of blocking the angiotensin II receptor in controlling blood pressure and preventing complications in diabetic patients.
The ABCD-2V trial will provide further information about appropriate blood pressure target levels for diabetics and the potential of the new angiotensin II receptor blocker Diovan to delay or prevent specific complications of diabetes.
The primary purpose of ABCD and ABCD-2V is to test whether intensive blood pressure control, as compared to moderate control, would prevent or slow the progression of diabetes-related conditions such as nerve damage, eye and kidney damage, stroke and heart attacks.
ABCD-2V is funded by a grant from Novartis Pharma AG, the developer of valsartan.
21, 1998, in response to the University of Colorado Health Sciences Center announcement that the ABCD study is continuing as ABCD-2V with the angiotensin II receptor blocker (ARB), Diovan(R) (valsartan):
Continuing as ABCD-2V (Appropriate Blood Pressure Control in Diabetes - Part Two with Valsartan), the study is the first to explore the benefits of an ARB, not only in treating adult (type 2) diabetes patients with high blood pressure, but also those adults (type 2) diabetes patients with normal blood pressure.
We are embarking upon landmark clinical initiatives like ABCD-2V because we believe the mechanism of action of Diovan may provide benefits beyond lowering blood pressure -- affecting long-term outcomes and saving lives," said William Jenkins, M.
ABCD-2V is investigating the ability of the ARB Diovan to prevent or delay the onset of damage in all of these key target areas in adult (type 2) diabetes patients with either normal or high blood pressure.